Evidence map›Paper›PMID 40109357›Full record

ReviewJournal of ophthalmology2025

Role of Tau Protein Hyperphosphorylation in Diabetic Retinal Neurodegeneration.

Jingyu Mu, Zengrui Zhang, Chao Jiang, Haoming Geng, Junguo Duan

Abstract readReview
In one paragraph

Review in Journal of ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Interferon-mediated regulation of the neurovascular unit in diabetic retinopathy.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jingyu MuEye School of Chengdu University of TCM, Chengdu, Sichuan, China.ORCID https://orcid.org/0000-0002-6121-258X
Zengrui ZhangEye School of Chengdu University of TCM, Chengdu, Sichuan, China.ORCID https://orcid.org/0000-0001-9129-5892
Chao JiangCollege of Life and Health Sciences, Institute of Neuroscience, Northeastern University, Shenyang, China.ORCID https://orcid.org/0009-0002-8528-9503
Haoming GengEye School of Chengdu University of TCM, Chengdu, Sichuan, China.ORCID https://orcid.org/0009-0008-4615-0473
Junguo DuanEye School of Chengdu University of TCM, Chengdu, Sichuan, China.ORCID https://orcid.org/0009-0009-3858-077X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetic retinal neurodegeneration (DRN) is an early manifestation of diabetic retinopathy (DR) characterized by neurodegeneration that precedes microvascular abnormalities in the retina. DRN is characterized by apoptosis of retinal ganglion cells (involves alterations in retinal ganglion cells [RGCs], photoreceptors, amacrine cells and bipolar cells and so on), reactive gliosis, and reduced retinal neuronal function. Tau, a microtubule-associated protein, is a key mediator of neurotoxicity in neurodegenerative diseases, with functions in phosphorylation-dependent microtubule assembly and stabilization, axonal transport, and neurite outgrowth. The hyperphosphorylated tau (p-tau) loses its ability to bind to microtubules and aggregates to form paired helical filaments (PHFs), which further form neurofibrillary tangles (NFTs), leading to abnormal cell scaffolding and cell death. Studies have shown that p-tau can cause degeneration of RGCs in DR, making tau pathology a new pathophysiological model for DR. Here, we review the mechanisms by which p-tau contribute to DRN, including insulin resistance or lack of insulin, mitochondrial damage such as mitophagy impairment, mitochondrial axonal transport defects, mitochondrial bioenergetics dysfunction, and impaired mitochondrial dynamics, Abeta toxicity, and inflammation. Therefore, this article proposes that tau protein hyperphosphorylation plays a crucial role in the pathogenesis of DRN and may serve as a novel therapeutic target for combating DRN.

Indexed as

abetadiabetic retinal neurodegenerationdiabetic retinopathyretinal ganglion cellstau

Identifiers

PMID40109357
PMCPMC11922625

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.